Your browser doesn't support javascript.
loading
Targeted reduction of CCR4⁺ cells is sufficient to suppress allergic airway inflammation.
Honjo, Akifumi; Ogawa, Hirohisa; Azuma, Masahiko; Tezuka, Toshifumi; Sone, Saburo; Biragyn, Arya; Nishioka, Yasuhiko.
Afiliação
  • Honjo A; Department of Respiratory Medicine & Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan. Electronic address: aki1078@ceres.ocn.ne.jp.
Respir Investig ; 51(4): 241-9, 2013 Dec.
Article em En | MEDLINE | ID: mdl-24238232
BACKGROUND: Bronchial asthma is characterized by allergic airway inflammation involving C-C chemokine receptor type 4 (CCR4)-positive Th2 cells. As such, we hypothesize that the disease can be alleviated by targeted-elimination of CCR4⁺ cells. Thymus and activation-regulated chemokine (TARC)-PE38, a TARC fused the exotoxin fragment PE38 from Pseudomonas aeruginosa, has been shown to efficiently kill CCR4⁺ cells by delivering the exotoxin fragment PE38 into CCR4⁺ cells. To test our hypothesis, we examined whether TARC-PE38 could suppress allergic airway inflammation in a mouse model of house dust mite (HDM)-induced allergic airway inflammation. METHODS: We evaluated the effect of TARC-PE38 on the major characteristics of HDM-induced allergic airway inflammation. Airway hyperresponsiveness, lung histopathology, lung Th1/Th2 cell populations, and concentrations of Th1/Th2 cytokines in the lungs were assessed in HDM-sensitized and challenged mice in the presence and absence of TARC-PE38. RESULTS: TARC-PE38 efficiently suppressed allergic airway inflammation by significantly reducing airway hyperresponsiveness, the overall area of inflammation, and goblet cell hyperplasia. In HDM-sensitized and challenged mice, TARC-PE38 specifically reduced the numbers of CCR4⁺ cells. This reduction was associated with a significant decrease in the production of Th2 cytokines in the airway,and a decrease in the number of leukocytes, including macrophages, eosinophils and lymphocytes, within the subepithelial area of the lungs and airway lumen. TARC-PE38 had noeffect on Th1 cells. CONCLUSION: Our data suggest that the elimination of CCR4⁺ cells via TARC-PE38 treatment is sufficient to control allergic airway inflammation and airway hyperresponsiveness.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Asma / Proteínas Recombinantes de Fusão / Células Th2 / Exotoxinas / Quimiocina CCL17 / Receptores CCR4 / Terapia de Alvo Molecular Idioma: En Ano de publicação: 2013 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Asma / Proteínas Recombinantes de Fusão / Células Th2 / Exotoxinas / Quimiocina CCL17 / Receptores CCR4 / Terapia de Alvo Molecular Idioma: En Ano de publicação: 2013 Tipo de documento: Article